Globus Medical Inc. Class A Common Stock vs Northrop Grumman Corporation — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Northrop Grumman Corporation trades at $497 (market cap $68.39B). The key difference: Northrop Grumman Corporation is far larger — about 6.7× Globus Medical Inc. Class A Common Stock's market cap, and Northrop Grumman Corporation pays a 2.05% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Northrop Grumman Corporation for 82 Days on average.
| GMED | NOC | |
|---|---|---|
Market Cap | $10.25B | $68.39B |
Volume | 1,108,124 | 823,323 |
Sector | Health | Industrials |
52-Week High | $96.82 | $768.02 |
52-Week Low | $58.33 | $473.46 |
Typical Hold Time | 0 Days | 82 Days |
Enterprise Value | $9.76B | $82.37B |
Dividend Yield | — | 2.05% |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Northrop Grumman (NOC) trades at $495.69, up 2.2% on the day, amid a bearish technical signal but strong fundamentals. The company has beaten earnings estimates for the last three quarters, with a net income margin of 10.48% and a P/E ratio of 15.3. Recent news highlights a $20 billion Navy fighter contract loss to Boeing, though the company maintains a record backlog and a dividend payout.
The outlook is mixed: analyst consensus is bullish with a $595.69 price target, but technical indicators and recent contract loss pose near-term risks. Long-term growth is supported by defense spending and key programs like the B-21 bomber, though competitive pressures and execution risks remain.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →